Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback